A number of stocks fell in the afternoon session after the White House announced a new round of steep global tariffs, ...

UiPath stands out with improving sales momentum, profitability, and a raised full-year outlook. Read why I remain bullish ...

PATH's enterprise AI edge and valuation advantage over APP make it the smarter buy in this AI-driven tech faceoff.

UiPath's market leadership in the RPA market remains compelling, significantly aided by the growing ARR and the rich cash ...

UiPath (PATH) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.

UiPath PATH, a key player in the robotic process automation (“RPA”) market, is trading at a forward 12-month price-to-sales (P/S) ratio of 4.12X, significantly below the industry average of 5 ...

UiPath (PATH) has been one of the most searched-for stocks on Zacks.com lately. So, you might want to look at some of the ...

UiPath PATH, a key player in the robotic process automation (“RPA”) market, is trading at a forward 12-month price-to-sales (P/S) ratio of 4.12X, significantly below the industry average of 5.75X.

PATH jumps 36% in three months as strong partnerships, solid growth and discounted valuation draw investor interest.

In the latest close session, UiPath (PATH) was down 2.38% at $12.32. The stock trailed the S&P 500, which registered a daily gain of 0.07%. On the other hand, the Dow registered a loss of 0.7%, and ...

U.S. District Judge John Cronan for the Southern District of New York found that investors represented by Bleichmar Fonti & ...